Yes, Humacyte reported quarterly financial results where its reported revenue figures fell short of consensus Wall Street analyst estimates. Although early commercial sales of its flagship bioengineered vessels demonstrated sequential growth, the absolute revenue metrics did not meet aggressive market expectations, contributing to near-term downward revisions in institutional earnings forecasts.